- Home
- EDF vs RNAC Comparison
EDF vs RNAC Comparison
Compare EDF & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDF | RNAC |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 214.8M |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | EDF | RNAC |
|---|---|---|
| Price | $5.06 | $8.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 284.4K | 181.2K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.14 | $5.98 |
| 52 Week High | $5.34 | $16.79 |
Technical Indicators
Market Signals| Indicator | EDF | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 55.73 |
| Support Level | $5.05 | $6.41 |
| Resistance Level | $5.19 | $10.49 |
| Average True Range (ATR) | 0.10 | 0.81 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 59.37 | 58.12 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.